The U.S. Food and Drug Administration (FDA) announced on Nov. 6 that long-term use of Plavix (clopidogrel) does not change the overall risk of death in cardiovascular disease patients.  The determination was based on a meta-analysis of long-term trial results, including the DAPT Trial.

According to the Agency, “the results indicate that long-term (12 months or longer) dual antiplatelet therapy with clopidogrel and aspirin do not appear to change the overall risk of death when compared to short-term (6 months or less) clopidogrel and aspirin, or aspirin alone.”

Read the FDA announcement.

Keywords: Aspirin, Cardiovascular Diseases, Platelet Aggregation Inhibitors, Ticlopidine, United States Food and Drug Administration

< Back to Listings